Media

Lupin Launches Rivaroxaban Tablets USP, 2.5mg in the United States

Lupin Secures a Place in the Prestigious S&P Global Sustainability Yearbook 2025

Lupin Receives EIR from U.S. FDA for its Somerset Manufacturing Facility

Lupin Receives “A-” Leadership Rating from CDP in Two Categories – Climate Change and Water Security

Lupin and Natco Receive Approval from U.S. FDA for Bosentan Tablets for Oral Suspension

Lupin Receives Tentative Approval from U.S. FDA for Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Tablets

Lupin Announces Closure of Inspection by U.S. FDA at its Somerset Facility with No Observations

Lupin Receives Tentative Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Gel

Lupin Receives EIR from U.S. FDA for its Pithampur Unit-1 Facility with VAI Classification